Thermo Fisher Scientific (NYSE:TMO) Announces Earnings Results, Beats Estimates By $0.28 EPS

Thermo Fisher Scientific (NYSE:TMO) posted its earnings results on Wednesday. The medical research company reported $6.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $0.28, FiscalAI reports. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The business had revenue of $12.14 billion for the quarter, compared to analyst estimates of $11.95 billion. During the same period last year, the business posted $5.79 EPS. Thermo Fisher Scientific’s revenue was up 9.1% compared to the same quarter last year.

Here are the key takeaways from Thermo Fisher Scientific’s conference call:

• Thermo Fisher raised its 2026 outlook, increasing revenue guidance to $47.7 billion–$48.2 billion, organic growth guidance to 4%, adjusted EPS guidance to $25.13–$25.43, and free cash flow guidance to $7.0 billion–$7.5 billion.
• Third-quarter performance exceeded expectations, with revenue up 9% to $12.14 billion, organic growth of 6%, adjusted EPS up 15% to $6.68, and adjusted operating margin expanding 120 basis points to 24.5%. Growth was led by Pharma Services, clinical research, electron microscopy, and improving biotech demand.
• Management reported continued strengthening in pharma and biotech customer activity, including low-to-mid/high-single-digit growth across key areas, improving biotech funding and confidence, and strong demand for clinical research, bioproduction, and semiconductor-related electron microscopy.
• The quarter benefited from approximately $60 million of net tariff-refund recovery, contributing $0.15 to adjusted EPS, although the company reinvested part of the proceeds in AI deployment, Pharma Services capacity, and employee investments. The refund benefit is largely one-time, while fourth-quarter organic growth guidance remains at 4% after some Pharma Services activity shifted into the third quarter.
• Thermo Fisher highlighted expanding AI capabilities across instruments and services, including AI-enabled cryo-electron microscopy workflows and a clinical research assistant, while the Clario acquisition and bioproduction investments are reportedly generating strong customer adoption and potential revenue synergies.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $676.09 on Friday. The firm’s 50-day moving average is $644.01 and its 200-day moving average is $553.96. The company has a market cap of $249.98 billion, a price-to-earnings ratio of 36.37, a PEG ratio of 2.89 and a beta of 0.87. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.18 and a current ratio of 1.81. Thermo Fisher Scientific has a 52-week low of $435.27 and a 52-week high of $705.78.

Wall Street Analysts Forecast Growth

TMO has been the topic of several research analyst reports. Stifel Nicolaus raised their price target on Thermo Fisher Scientific from $650.00 to $775.00 and gave the company a “buy” rating in a research report on Thursday. Sanford C. Bernstein began coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They set a “market perform” rating and a $520.00 price objective for the company. Citigroup restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Friday. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 3rd. Finally, Royal Bank Of Canada lifted their price target on Thermo Fisher Scientific from $580.00 to $730.00 and gave the stock a “sector perform” rating in a research report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $675.52.

Insider Activity at Thermo Fisher Scientific

In related news, CAO Joseph Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Lisa Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the sale, the vice president directly owned 14,784 shares in the company, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 73,768 shares of company stock worth $44,122,820 in the last three months. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q3 beat and stronger outlook: Thermo Fisher reported third-quarter revenue of $12.14 billion, up 9.1% year over year, while adjusted EPS of $6.68 exceeded the $6.40 consensus estimate. Organic growth reached 6%, margins improved, and management raised its full-year 2026 revenue-growth and earnings outlook. Thermo Fisher Scientific Reports Third Quarter 2026 Results
• Positive Sentiment: Analysts remain bullish: TD Cowen raised its price target to $810 and retained a “buy” rating. Stifel Nicolaus lifted its target to $775, while Robert W. Baird raised its target to $756 and maintained an “outperform” rating. The revisions reflect confidence in recovery across clinical research, bioproduction and laboratory products.
• Positive Sentiment: Industry growth supports long-term demand: Research indicates the peptide-synthesis market could expand from $0.98 billion in 2026 to $1.54 billion by 2031, aided by GLP-1 drug development. Thermo Fisher is among the companies positioned to benefit from increased pharmaceutical and research activity. Global Peptide Synthesis Market Forecast
• Neutral Sentiment: Peer comparison: A new survey compares Thermo Fisher with Twist Bioscience, but it does not provide a clear new company-specific catalyst for TMO. Twist Bioscience versus Thermo Fisher Scientific
• Negative Sentiment: Options activity signals caution: Heavy put-option buying, including activity roughly 52% above average, suggests some traders are hedging against a pullback or positioning defensively after the earnings release. Thermo Fisher Scientific Stock Sees Heavy Put Option Buying
• Negative Sentiment: Muted earnings reaction and valuation risk: The strong report has not produced a sustained rally, potentially because TMO trades near its 12-month high at a forward-looking premium valuation. Investors may be demanding clearer evidence that the end-market recovery can justify the stock’s elevated earnings multiple.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.